Persistence of CRISPR/Cas9 Gene Edited Hematopoietic Stem Cells Following Transplantation: A Systematic Review and Meta-Analysis of Preclinical Studies
Authors:
Open Access
- 5 March 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (7) , 996-1007
Abstract
Gene editing blood-derived cells is an attractive approach to cure selected monogenic diseases but remains experimental. A systematic search of preclinical controlled studies is needed to determine the persistence of edited cells following reinfusion. All studies identified in our systematic search (to 20 October 2020) examining the use of CRISPR/Cas9 gene editing in blood-derived cells for transplantation were included. Meta-analysis was performed to determine the engraftment and persistence of gene edited cells. A total of 3538 preclinical studies were identified with 15 published articles meeting eligibility for meta-analysis. These in vivo animal studies examined editing of hemoglobin to correct sickle cell disease (eight studies), inducing resistance to acquired immunodeficiency syndrome (two studies), and six other monogenic disorders (single studies). CRISPR-Cas9 edited hematopoietic stem and progenitor cells demonstrated equivalent early engraftment compared to controls in meta-analysis but persistence of gene-edited cells was reduced at later time points and in secondary transplant recipients. Subgroup analysis in studies targeting the hemoglobin gene revealed a significant reduction in the persistence of gene-edited cells whether homology-directed repair or nonhomologous end-joining were used. No adverse side effects were reported. Significant heterogeneity in study design and outcome reporting was observed and the potential for bias was identified in all studies. CRISPR-Cas9 gene edited cells engraft similarly to unedited hematopoietic cells. Persistence of gene edited cells, however, remains a challenge and improved methods of targeting hematopoietic stem cells are needed. Reducing heterogeneity and potential risk of bias will hasten the development of informative clinical trials.Keywords
Funding Information
- Canadian Blood Services Foundation
This publication has 56 references indexed in Scilit:
- Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal ExperimentsPLOS Medicine, 2013
- Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsThe Lancet, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteriaProceedings of the National Academy of Sciences, 2012
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- CRISPR RNA maturation by trans-encoded small RNA and host factor RNase IIINature, 2011
- Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primatesJournal of Clinical Investigation, 2010
- Small CRISPR RNAs Guide Antiviral Defense in ProkaryotesScience, 2008
- Regulation of DNA repair throughout the cell cycleNature Reviews Molecular Cell Biology, 2008
- Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sitesMolecular Microbiology, 1993